1. Signaling Pathways
  2. Neuronal Signaling
  3. Monoamine Oxidase

Monoamine Oxidase

MAO

Monoamine oxidases (MAO) are a family of enzymes that catalyze the oxidation of monoamines. They are found bound to the outer membrane of mitochondria in most cell types in the body. They belong to the protein family of flavin-containing amine oxidoreductases. Monoamine oxidases catalyze the oxidative deamination of monoamines. Oxygen is used to remove an amine group from a molecule, resulting in the corresponding aldehyde and ammonia. Monoamine oxidases contain the covalently bound cofactor FAD and are, thus, classified as flavoproteins. Because of the vital role that MAOs play in the inactivation of neurotransmitters, MAO dysfunction is thought to be responsible for a number of psychiatric and neurological disorders. MAO-A inhibitors act as antidepressant and antianxiety agents, whereas MAO-B inhibitors are used alone or in combination to treat Alzheimer’sand Parkinson’s diseases.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16731
    Sembragiline
    Inhibitor
    Sembragiline (EVT 302) is a potent, selective and reversible monoamine oxidase B (MAO-B) inhibitor. Sembragiline reduces the metabolism of dopamine and other amine neurotransmitters by inhibiting the activity of the MAO-B enzyme, thereby potentially increasing the concentration of these neurotransmitters in the brain. Inhibition of the MAO-B enzyme also reduces the formation of toxic reactive oxygen species (ROS) that play a role in the pathological process of AD. Sembragiline has good oral activity and blood-brain barrier permeability. Sembragiline can be used in studies of AD, especially in patients with AD who show increased MAO-B activity.
    Sembragiline
  • HY-149978
    LSD1-IN-26
    Inhibitor
    LSD1-IN-26 (compound 12u) is a potent LSD1 inhibitor, with an IC50 of 25.3 nM. LSD1-IN-26 also inhibits MAO-A (IC50=1234.57 nM) and MAO-B (IC50=3819.27 nM). LSD1-IN-26 significantly induces apoptosis in MGC-803 cells. LSD1-IN-26 can be used for gastric cancer research.
    LSD1-IN-26
  • HY-151885
    Dual AChE-MAO B-IN-3
    Inhibitor
    Dual AChE-MAO B-IN-3 (compound C10) is a potent dual AChE/MAO-B inhibitior, with IC50 values of 0.58 and 0.41 μM, respectively. Dual AChE-MAO B-IN-3 is a dual-binding inhibitor bound to both the catalytic anionic site and peripheral anionic site of AChE. Dual AChE-MAO B-IN-3 can be used for Alzheimer’s disease (AD) research.
    Dual AChE-MAO B-IN-3
  • HY-143438
    2-PAT
    Inhibitor
    2-PAT, an analogue of Rasagiline and Selegiline, a reversible MAO-A inhibitor with an IC50 of 0.721 µM. 2-PAT is an inactivator of MAO-B with an IC50 of 14.6 µM. 2-PAT has the potential for Parkinson’s disease and depression research.
    2-PAT
  • HY-162303
    C175-0062
    Inhibitor
    C175-0062 is a monoamine oxidase B (MAO-B) inhibitor. C175-0062 can be used for the research of neurodegenerative disorders, including Parkinson's disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS).
    C175-0062
  • HY-101392R
    Harmane (Standard)
    Inhibitor
    Harmane (Standard) is the analytical standard of Harmane. This product is intended for research and analytical applications. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively). Harmane exhibits comutagenic effect.
    Harmane (Standard)
  • HY-106741
    Bazinaprine
    Inhibitor
    Bazinaprine (SR 95191), a derivative of Minaprine (HY-B0884), is an orally active inhibitor of type A monoamine oxidase (MAO). Bazinaprine can be used for research of depression.
    Bazinaprine
  • HY-162830
    5-LOX/MAOs-IN-1
    Inhibitor
    5-LOX/MAOs-IN-1 (compound 3) is a 5-LOX/MAOs inhibitor and a potent free radical scavenger with antioxidant properties. 5-LOX/MAOs-IN-1 also showed neuroprotective activity in oxidative stress-damaged cell models and can activate the neurogenesis microenvironment of adult mouse neural stem cells. 5-LOX/MAOs-IN-1 can be used for the study of neurodegenerative diseases.
    5-LOX/MAOs-IN-1
  • HY-163031
    MAO-B-IN-28
    Inhibitor
    MAO-B-IN-28 (compound 10e) is a potent hMAO-B inhibitor with an IC50 of 1.9±0.5 nM. MAO-B-IN-28 can be used as a candidate for neurodegenerative diseases research.
    MAO-B-IN-28
  • HY-149527
    MAO-B-IN-23
    Inhibitor
    MAO-B-IN-23 (Compound 11f) is a reversible and competitive MAO-B inhibitor (IC50: 1.44 μM, Ki: 0.51 μM).
    MAO-B-IN-23
  • HY-B1111S
    Amitraz-d6
    Inhibitor
    Amitraz-d6 (BTS-27419-d6) is the deuterium labeled Amitraz. Amitraz is a non-systemic acaricide and insecticide, with alpha-adrenergic agonist activity, interaction with octopamine receptors of the central nervous system and inhibition of monoamine oxidases and prostaglandin synthesis.
    Amitraz-d<sub>6</sub>
  • HY-119395A
    Kynuramine dihydrobromide
    Chemical
    Kynuramine dihydrobromide, an endogenously occurring amine, is a fluorescent substrate of plasma amine oxidase.
    Kynuramine dihydrobromide
  • HY-173288
    MAO-B-IN-40
    Inhibitor
    MAO-B-IN-40 (3a), a MAOB inhibitor (IC50 = 0.493 μM for hMAOB), demonstrates robust neuroprotective and antioxidant effect. MAO-B-IN-40 (3a) can be used in the research of Parkinson’s disease.
    MAO-B-IN-40
  • HY-158334
    NDs-IN-1
    Inhibitor
    (Neurodegenerative diseases) NDs-IN-1 (Compound 3g) inhibits the activities of key enzymes such as hBACE-1, hAChE and hMAO-B. NDs-IN-1 is a novel non-covalent multi-target inhibitor. NDs-IN-1 is mainly used in the study of neurodegenerative diseases.
    NDs-IN-1
  • HY-172460
    AChE/BChE/MAO-B-IN-5
    Inhibitor
    AChE/BChE/MAO-B-IN-5 is a multitarget inhibitor of cholinesterases (AChE and BChE) and monoamine oxidase MAO-B with blood–brain barrier permeability. It exhibits IC50 values of 0.24 µM, 6.29 µM, and 0.11 µM against AChE, BChE, and MAO-B, respectively. AChE/BChE/MAO-B-IN-5 shows promise for research in the field of neurodegenerative diseases such as Alzheimer's disease.
    AChE/BChE/MAO-B-IN-5
  • HY-157934
    MAO-IN-4
    Inhibitor
    MAO-IN-4 (Compound 2l) is a monoamine oxidase (MAO) inhibitor, with IC50 values of 0.07 and 0.75 μM for MAO-A and MAO-B Enzymes, respectively. MAO-IN-4 can be used for the research of depression and Parkinson’s disease (PD).
    MAO-IN-4
  • HY-172101
    AChE/MAO-B-IN-7
    Inhibitor
    AChE/MAO-B-IN-7 (VAV-8) is a blood-brain permeable dual inhibitor of acetylcholinesterase (AchE) and MAO-B agent. AChE/MAO-B-IN-7 can also inhibit Aβ42 aggregation for use in Alzheimer's disease (AD) research.
    AChE/MAO-B-IN-7
  • HY-129479
    Almoxatone
    Inhibitor
    Almoxatone is an orally effective, long-acting inhibitor of MAO-B.
    Almoxatone
  • HY-W008566R
    Norharmane (Standard)
    Inhibitor
    Norharmane (Standard) is the analytical standard of Norharmane. This product is intended for research and analytical applications. Norharmane (Norharman), a β-carboline alkaloid, is a potent and reversible monoamine oxidase inhibitor, with IC50 values of 6.5 and 4.7 μM for MAO-A and MAO-B, respectively. Norharmane causes antidepressant responses. Norharmane is also a prospective anti-cancer photosensitizer. Norharmane alters polar auxin transport (PAT) by inhibiting PIN2, PIN3 and PIN7 transport proteins, thus causing a significant inhibitory effect on the growth of Arabidopsis thaliana seedlings.
    Norharmane (Standard)
  • HY-17447B
    (1S,2R)-Tranylcypromine hydrochloride
    Inhibitor
    (1S,2R)-Tranylcypromine ((1S,2R)-SKF 385) hydrochloride is a potent antidepressant agent. (1S,2R)-Tranylcypromine hydrochloride can inhibits MAO and LSD1.
    (1S,2R)-Tranylcypromine hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.